Skip to main content
SpringerLink
Log in

Lung Cancer

  • Chapter
PET and PET-CT in Oncology

  • 295 Accesses

Abstract

Lung cancer is the most common cause of cancer-related death in the western world, with approximately 3 million new cases per year world-wide, of which more than 200,000 are in the European Union. In men, mortality from lung cancer is much higher than from the second in rank, prostate cancer. In women, breast cancer is the leading cause of cancer death in many countries, but lung cancer also accounts for 10 %.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Doll R, Peto R (1978) Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Commun Health 32: 303–313

    Article  CAS  Google Scholar 

  2. Denissenko MF, Pao A, Tang M et al (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430–432

    Article  PubMed  CAS  Google Scholar 

  3. Darby S, Hill D, Doll R (2001) Radon: a likely carcinogen at all exposures. Ann Oncol 12:1341–1351

    Article  PubMed  CAS  Google Scholar 

  4. Swensen SJ, Jett JR, Sloan JA et al (2002) Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 165:508–513

    PubMed  Google Scholar 

  5. World Health Organization (1982) Histological typing of lung tumors, 2nd edn. Am J Clin Pathol 77:123–136

    Google Scholar 

  6. Travis WD, Colby TV, Corrin B et al (1999) Histological typing of lung and pleural tumours. WHO international classification of lung tumours, 3rd edn. Springer, Berlin Heidelberg New York

    Book  Google Scholar 

  7. Cummings SR, Lillington GA, Richard RJ (1986) Managing solitary pulmonary nodules. The choice of strategy is a “close call”. Am Rev Respir Dis 134:453–460

    PubMed  CAS  Google Scholar 

  8. Yankelevitz DF, Henschke CI (1997) Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol 168:325–328

    PubMed  CAS  Google Scholar 

  9. Arroliga AC, Matthay RA (1993) The role of bronchoscopy in lung cancer. Clin Chest Med 14:87–98

    PubMed  CAS  Google Scholar 

  10. Santambrogio L, Nosotti M, Bellaviti N et al (1997) CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: a prospective, randomized study of immediate cytologic evaluation. Chest 112:423–425

    Article  PubMed  CAS  Google Scholar 

  11. Larscheid RC, Thorpe PE, Scott WJ (1998) Percutaneous transthoracic needle aspiration biopsy: a comprehensive review of its current role in the diagnosis and treatment of lung tumors. Chest 114:704–709

    Article  PubMed  CAS  Google Scholar 

  12. Michiels E, Demedts M (1991) Pitfalls of transthoracic needle aspiration biopsy. Acta Clin Belg 46:359–363

    PubMed  CAS  Google Scholar 

  13. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    Article  PubMed  CAS  Google Scholar 

  14. Jett JR, Scott WJ, Rivera MP et al (2003) Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 123 [Suppl 1]:221S–225S

    Article  PubMed  Google Scholar 

  15. Vansteenkiste J, De Leyn P, Deneffe G et al (1998) Present status of induction treatment for N2 non-small cell lung cancer: a review. Eur J Cardiothorac Surg 13:1–12

    Article  PubMed  CAS  Google Scholar 

  16. Rosell R, Gomez Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158

    Article  PubMed  CAS  Google Scholar 

  17. Vansteenkiste JF, Vandebroek JE, Nackaerts KL et al (2001) Clinical benefit response in advanced non-small cell lung cancer. A multicenter prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230

    Article  PubMed  CAS  Google Scholar 

  18. Numico G, Russi E, Merlano M (2001) Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32:213–226

    Article  PubMed  CAS  Google Scholar 

  19. Bittner RC, Felix R (1998) Magnetic resonance (MR) imaging of the chest: state-of-the-art. Eur Respir J 11:1392–1404

    Article  PubMed  CAS  Google Scholar 

  20. McLoud TC, Bourgouin PM, Greenberg RW et al (1992) Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 182:319–323

    PubMed  CAS  Google Scholar 

  21. Staples CA, Miller RR, Evans KG et al (1988) Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 167:367–372

    PubMed  CAS  Google Scholar 

  22. Webb WR, Gatsouris S, Zerhouni EA et al (1991) CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiology Diagnostic Oncology Group. Radiology 178:705–713

    PubMed  CAS  Google Scholar 

  23. Dillemans B, Deneffe G, Verschakelen J et al (1994) Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg 8:37–42

    Article  PubMed  CAS  Google Scholar 

  24. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723

    Article  PubMed  CAS  Google Scholar 

  25. Quint LE, Tummala S, Brisson LJ et al (1996) Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62:246–250

    Article  PubMed  CAS  Google Scholar 

  26. Parker SL, Tong T, Bolden S et al (1997) Cancer statistics 1997. CA Cancer J Clin 47:5–27

    Article  PubMed  CAS  Google Scholar 

  27. American Thoracic Society (ATS), European Respiratory Society (ERS) (1997) Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 156:320–332

    Google Scholar 

  28. Goldstraw P, Rocmans P, Ball D et al (1994) Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report. Lung Cancer 11 [Suppl 3]:1–4

    Article  Google Scholar 

  29. Silvestri GA, Tanoue LT, Margolis ML et al (2003) The non-invasive staging of non-small cell lung cancer: the guidelines. Chest 123 [Suppl 1]:147S–156S

    Article  PubMed  Google Scholar 

  30. Pantel K, Izbicki J, Passlick B et al (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases. Lancet 347:649–653

    Article  PubMed  CAS  Google Scholar 

  31. Martini N, Bains MS, Burt ME et al (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120–129

    Article  PubMed  CAS  Google Scholar 

  32. Pairolero PC, Williams DE, Bergstralh EJ et al (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:331–338

    Article  PubMed  CAS  Google Scholar 

  33. Yano T, Yokoyama H, Inoue T et al (1994) The first site of recurrence after complete resection in non-small cell carcinoma of the lung. Comparison between pNo disease and pN2 disease. J Thorac Cardiovasc Surg 108:680–683

    PubMed  CAS  Google Scholar 

  34. De Ruysscher D, Vansteenkiste J (2000) Chest radiotherapy in limited stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 55:1–9

    Article  PubMed  Google Scholar 

  35. Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer — what limits limited disease? Lung Cancer 37:271–276

    Article  PubMed  Google Scholar 

  36. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  37. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  38. Martini N, Kris MG, Flehinger B et al (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365–1374

    Article  PubMed  CAS  Google Scholar 

  39. Strauss GM, Herndon JE, Sherman DD et al (1992) Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10:1237–1244

    PubMed  CAS  Google Scholar 

  40. Choi NC, Carey RW, Daly W et al (1997) Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15:712–722

    PubMed  CAS  Google Scholar 

  41. Pisters KM, Kris MG, Gralla RJ et al (1993) Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762

    PubMed  CAS  Google Scholar 

  42. Crino L, Mosconi AM, Scagliotti GV et al (1999) Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 17:2081–2085

    PubMed  CAS  Google Scholar 

  43. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

    PubMed  CAS  Google Scholar 

  44. Sazon DA, Santiago SM, Soo Hoo GW et al (1996) Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 153:417–421

    PubMed  CAS  Google Scholar 

  45. Lowe VJ, Fletcher JW, Gobar L et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075–1084

    PubMed  CAS  Google Scholar 

  46. Duhaylongsod FG, Lowe VJ, Patz EF et al (1995) Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 110:130–139

    Article  PubMed  CAS  Google Scholar 

  47. Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943–948

    PubMed  CAS  Google Scholar 

  48. Nackaerts K, Stroobants S, Vansteenkiste J et al (1997) The use of positron emission tomography (PET) in the differential diagnosis of indeterminate solitary pulmonary lesions, 10th edn.

    Google Scholar 

  49. Patz EF, Lowe VJ, Hoffman JM et al (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487–490

    PubMed  Google Scholar 

  50. Bury T, Dowlati A, Paulus P et al (1996) Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 9:410–414

    Article  PubMed  CAS  Google Scholar 

  51. Lowe VJ, Hoffman JM, DeLong DM et al (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35:1771–1776

    PubMed  CAS  Google Scholar 

  52. Gupta N, Gill H, Graeber G et al (1998) Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 114:1105–1111

    Article  PubMed  CAS  Google Scholar 

  53. Gould MK, Maclean CC, Kuschner WG et al (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914–924

    Article  PubMed  CAS  Google Scholar 

  54. Scott WJ, Schwabe JL, Gupta NC et al (1994) Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 58:698–703

    Article  PubMed  CAS  Google Scholar 

  55. Kubota K, Matsuzawa T, Fujiwara T et al (1990) Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 31:1927–1932

    PubMed  CAS  Google Scholar 

  56. Dewan NA, Gupta NC, Redepenning LS et al (1993) Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 104: 997–1002

    Article  PubMed  CAS  Google Scholar 

  57. Erasmus JJ, McAdams HP, Patz EF et al (1998) Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170:1369–1373

    PubMed  CAS  Google Scholar 

  58. Higashi K, Ueda Y, Seki H et al (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39:1016–1020

    PubMed  CAS  Google Scholar 

  59. Kim BT, Kim Y, Lee KS et al (1998) Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 170:935–939

    PubMed  CAS  Google Scholar 

  60. Kapucu LO, Meltzer CC, Townsend DW et al (1998) Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 39: 1267–1269

    PubMed  CAS  Google Scholar 

  61. Brudin LH, Valind SO, Rhodes CG et al (1994) Fluorine-18 de-oxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21:297–305

    Article  PubMed  CAS  Google Scholar 

  62. Bakheet SM, Saleem M, Powe J et al (2000) F-18 fluorodeoxy-glucose chest uptake in lung inflammation and infection. Clin Nucl Med 25:273–278

    Article  PubMed  CAS  Google Scholar 

  63. Matthies A, Hickeson M, Cuchiara A et al (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875

    PubMed  Google Scholar 

  64. Gambhir SS, Shepherd JE, Shah BD et al (1998) Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 16:2113–2125

    PubMed  CAS  Google Scholar 

  65. Scott WJ, Shepherd J, Gambhir SS (1998) Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 66:1876–1883

    Article  PubMed  CAS  Google Scholar 

  66. Kosuda S, Ichihara K, Watanabe M et al (2000) Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 117:346–353

    Article  PubMed  CAS  Google Scholar 

  67. Carretta A, Landoni C, Melloni G et al (2000) 18-FDG positron emission tomography in the evaluation of malignant pleural diseases — a pilot study. Eur J Cardiothorac Surg 17:377–383

    Article  PubMed  CAS  Google Scholar 

  68. Erasmus JJ, McAdams HP, Rossi SE et al (2000) FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 175:245–249

    PubMed  CAS  Google Scholar 

  69. Gupta NC, Rogers JS, Graeber GM et al (2002) Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 122:1918–1924

    Article  PubMed  CAS  Google Scholar 

  70. Saunders CA, Dussek JE, O’Doherty MJ et al (1999) Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 67:790–797

    Article  PubMed  CAS  Google Scholar 

  71. Valk PE, Pounds TR, Hopkins DM et al (1995) Staging non-small cell lung cancer by whole-body positron emission to-mographic imaging. Ann Thorac Surg 60:1573–1581

    Article  PubMed  CAS  Google Scholar 

  72. Vansteenkiste JF, Stroobants SG, de Leyn PR et al (1998) Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16:2142–2149

    PubMed  CAS  Google Scholar 

  73. Kernstine KH, Stanford W, Mullan BF et al (1999) PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 68:1022–1028

    Article  PubMed  CAS  Google Scholar 

  74. Vansteenkiste JF, Stroobants SG, Dupont PJ et al (1998) FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur J Nucl Med 25: 1495–1501

    Article  PubMed  CAS  Google Scholar 

  75. Vansteenkiste JF, Stroobants SG, de Leyn PR et al (1997) Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Chest 112:1480–1486

    Article  PubMed  CAS  Google Scholar 

  76. Bury T, Paulus P, Dowlati A et al (1996) Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 9:2560–2564

    Article  PubMed  CAS  Google Scholar 

  77. Weng E, Tran L, Rege S et al (2000) Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol 23: 47–52

    Article  PubMed  CAS  Google Scholar 

  78. Dwamena BA, Sonnad SS, Angobaldo JO et al (1999) Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology 213:530–536

    PubMed  CAS  Google Scholar 

  79. Oliver TW, Bernardino ME, Miller JI et al (1984) Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology 153:217–218

    PubMed  Google Scholar 

  80. Nielsen ME, Heaston DK, Dunnick NR et al (1982) Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. AJR Am J Roentgenol 139:317–320

    PubMed  Google Scholar 

  81. Pagani JJ (1984) Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis. Cancer 53:1058–1060

    Article  PubMed  CAS  Google Scholar 

  82. Ettinghausen SE, Burt ME (1991) Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 9:1462–1466

    PubMed  CAS  Google Scholar 

  83. Erasmus JJ, Patz EF, McAdams HP et al (1997) Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:1357–1360

    PubMed  CAS  Google Scholar 

  84. Boland GW, Goldberg MA, Lee MJ et al (1995) Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194:131–134

    PubMed  CAS  Google Scholar 

  85. Maurea S, Mainolfi C, Bazzicalupo L et al (1999) Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 173:25–29

    PubMed  CAS  Google Scholar 

  86. Yun M, Kim W, Alnafisi N et al (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42: 1795–1797

    PubMed  CAS  Google Scholar 

  87. Patz EF, Erasmus JJ, McAdams HP et al (1999) Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology 212:56–60

    PubMed  Google Scholar 

  88. Weder W, Schmid RA, Bruchhaus H et al (1998) Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66:886–892

    Article  PubMed  CAS  Google Scholar 

  89. Marom EM, McAdams HP, Erasmus JJ et al (1999) Staging non-small cell lung cancer with whole-body PET. Radiology 212: 803–809

    PubMed  CAS  Google Scholar 

  90. Hustinx R, Paulus P, Jacquet N et al (1998) Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 9: 397–401

    Article  PubMed  CAS  Google Scholar 

  91. Delbeke D, Martin WH, Sandier MP et al (1998) Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133:510–515

    Article  PubMed  CAS  Google Scholar 

  92. Bury T, Barreto A, Daenen F et al (1998) Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244–1247

    Article  PubMed  CAS  Google Scholar 

  93. Schirrmeister H, Guhlmann A, Eisner K et al (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F-PET. J Nucl Med 40: 1623–1629

    PubMed  CAS  Google Scholar 

  94. Lassen U, Andersen P, Daugaard G et al (1998) Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission tomography. Clin Cancer Res 4:2591–2597

    PubMed  CAS  Google Scholar 

  95. Shuke N, Tonami N, Shintani H et al (1999) Differential uptake of TI-201 by small cell lung cancer in a patient with pneumoconiosis-related pulmonary nodules. Clin Nucl Med 24:687–690

    Article  PubMed  CAS  Google Scholar 

  96. Hauber HP, Bohuslavizki KH, Lund CH et al (2001) Positron emission tomography in the staging of small cell lung cancer: a preliminary study. Chest 119:950–954

    Article  PubMed  CAS  Google Scholar 

  97. Shen YY, Shiau YC, Wang JJ et al (2002) Whole-body 18F-2-de-oxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 22:1257–1264

    PubMed  Google Scholar 

  98. Chin R, McCain TW, Miller AA et al (2002) Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37:1–6

    Article  PubMed  Google Scholar 

  99. Ichiya Y, Kuwabara Y, Sasaki M et al (1996) A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 10:193–200

    Article  PubMed  CAS  Google Scholar 

  100. Kubota K, Yamada S, Ishiwata K et al (1993) Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study. Eur J Nucl Med 20:495–501

    Article  PubMed  CAS  Google Scholar 

  101. Vansteenkiste JF, Stroobants SG, de Leyn PR et al (1998) Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small cell lung cancer: a prospective pilot study. Ann Oncol 9:1193–1198

    Article  PubMed  CAS  Google Scholar 

  102. Vansteenkiste J, Stroobants S, Hoekstra C et al (2001) 18fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: a multi-center prospective study, 20th edn.

    Google Scholar 

  103. Ryu JS, Choi NC, Fischman AJ et al (2002) FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35:179–187

    Article  PubMed  Google Scholar 

  104. Akhurst T, Downey RJ, Ginsberg MS et al (2002) An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 73:259–266

    Article  PubMed  Google Scholar 

  105. Kubota K, Yamada S, Ishiwata K et al (1992) Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med 17:877–881

    Article  PubMed  CAS  Google Scholar 

  106. Inoue T, Kim EE, Komaki R et al (1995) Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36:788–793

    PubMed  CAS  Google Scholar 

  107. Patz EF, Lowe VJ, Hoffman JM et al (1994) Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 191:379–382

    PubMed  Google Scholar 

  108. Frank A, Lefkowitz D, Jaeger S et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32:1495–1512

    Article  PubMed  CAS  Google Scholar 

  109. Hebert ME, Lowe VJ, Hoffman JM et al (1996) Positron emis-sion tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radio-therapy: preliminary findings. Am J Clin Oncol 19:416–421

    Article  PubMed  CAS  Google Scholar 

  110. Bury T, Corhay JL, Duysinx B et al (1999) Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 14:1376–1380

    Article  PubMed  CAS  Google Scholar 

  111. Hicks RJ, Kalff V, Mac Manus MP et al (2001) The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on manage-ment and prognostic stratification. J Nucl Med 42:1605–1613

    PubMed  CAS  Google Scholar 

  112. Duhaylongsod FG, Lowe VJ, Patz EF et al (1995) Lung tumor growth correlates with glucose metabolism measured by flu-oride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348–1352

    Article  PubMed  CAS  Google Scholar 

  113. Vansteenkiste JF, Stroobants SG, de Leyn PR et al (1999) Prognostic importance of the Standardized Uptake Value on FDG-PET-scan in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol 17:3201–3206

    PubMed  CAS  Google Scholar 

  114. Ahuja V, Coleman RE, Herndon J et al (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918–924

    Article  PubMed  CAS  Google Scholar 

  115. Patz EF, Connolly J, Herndon J (2000) Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174:769–774

    PubMed  Google Scholar 

  116. Swensen SJ, Brown LR, Colby TV et al (1996) Lung nodule enhancement at CT: prospective findings. Radiology 201:447–455

    PubMed  CAS  Google Scholar 

  117. Seemann MD, Seemann O, Luboldt W et al (2000) Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT. Lung Cancer 29: 105–124

    Article  PubMed  CAS  Google Scholar 

  118. Schreurs AJ, Westermann CJ, van den Bosch JM et al (1992) A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 104: 1470–1475

    PubMed  CAS  Google Scholar 

  119. Jang HJ, Lee KS, Kwon OJ et al (1996) Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 199:485–488

    PubMed  CAS  Google Scholar 

  120. Vansteenkiste JF, de Leyn PR, Deneffe GJ et al (1997) Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. The Leuven Lung Cancer Group. Ann Thorac Surg 63:1441–1450

    Article  PubMed  CAS  Google Scholar 

  121. Gambhir SS, Hoh CK, Phelps ME et al (1996) Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 37:1428–1436

    PubMed  CAS  Google Scholar 

  122. Bury T, Dowlati A, Paulus P et al (1996) Staging of non-small cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23:204–206

    Article  PubMed  CAS  Google Scholar 

  123. Lewis P, Griffin S, Marsden P et al (1994) Whole-body 18F-flu-orodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265–1266

    Article  PubMed  CAS  Google Scholar 

  124. Nettelbladt OS, Sundin AE, Valind SO et al (1998) Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 39:640–647

    PubMed  CAS  Google Scholar 

  125. Sasaki M, Kuwabara Y, Yoshida T et al (2001) Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. Ann Nucl Med 15: 425–431

    Article  PubMed  CAS  Google Scholar 

  126. Yasukawa T, Yoshikawa K, Aoyagi H et al (2000) Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 41: 283–290

    PubMed  CAS  Google Scholar 

  127. Pieterman RM, Que TH, Elsinga PH et al (2002) Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 43:167–172

    PubMed  Google Scholar 

  128. Hara T, Inagaki K, Kosaka N et al (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41:1507–1513

    PubMed  CAS  Google Scholar 

  129. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336

    Article  PubMed  CAS  Google Scholar 

  130. Vesselle H, Grierson J, Muzi M et al (2002) In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine (18F-FLT) as a proliferation imaging tracer in humans: correlation of 18F-FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315–3323

    PubMed  CAS  Google Scholar 

  131. Buck AK, Schirrmeister H, Hetzel M et al (2002) 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62:3331–3334

    PubMed  CAS  Google Scholar 

  132. Van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393

    Article  Google Scholar 

  133. Tewson TJ, Krohn KA (1998) PET radiopharmaceuticals: state-of-the-art and future prospects. Semin Nucl Med 28:221–234

    Article  PubMed  CAS  Google Scholar 

  134. Alauddin MM, Shahinian A, Kundu RK et al (1999) Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol 26:371–376

    Article  PubMed  CAS  Google Scholar 

  135. Alauddin MM, Conti PS (1998) Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guani ne ( [18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 25:175–180

    Article  PubMed  CAS  Google Scholar 

  136. Price P, Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A:1924–1927

    Article  PubMed  CAS  Google Scholar 

  137. Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77

    PubMed  CAS  Google Scholar 

  138. Langen KJ, Braun U, Rota Kops E et al (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34:355–359

    PubMed  CAS  Google Scholar 

  139. Gorenberg M, Hallett WA, O’Doherty MJ (2002) Does diabetes affect (18)F-FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 29:1324–1327

    Article  PubMed  CAS  Google Scholar 

  140. Hoekstra CJ, Paglianiti I, Hoekstra OS et al (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27:731–743

    Article  PubMed  CAS  Google Scholar 

  141. Hoekstra CJ, Hoekstra OS, Stroobants SG et al (2002) Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304–1309

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Catholic University Leuven, Respiratory Oncology Unit (Department of Pulmonology) University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium

    J. F. Vansteenkiste (MD, PhD)

  2. Catholic University Leuven, PET-Center (Department of Nuclear Medicine) University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium

    S. S. Stroobants (MD, PhD)

Authors
  1. J. F. Vansteenkiste
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. S. Stroobants
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Vansteenkiste, J.F., Stroobants, S.S. (2004). Lung Cancer. In: PET and PET-CT in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18803-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18803-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62298-4

  • Online ISBN: 978-3-642-18803-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation